A complete guide to purifying monoclonal antibodies, bispecific antibodies, Fc fusion proteins, and ADCs using Protein A resin

In the global wave of biopharmaceutical innovation, antibody drugs have become key treatments in areas such as cancer, autoimmune diseases, and rare diseases. The forms of these drugs have expanded from classic monoclonal antibodies to bispecific antibodies, Fc fusion proteins, and antibody-drug conjugates (ADCs), among others. Downstream purification is a crucial step in the industrial production of antibody drugs, directly determining product purity, yield, and production cost. The four core chromatography media—monoclonal antibody purification media, bispecific antibody Protein A media, Fc fusion protein purification media, and ADC Protein A media—correspond to the purification needs of different molecules, together forming the technical foundation of downstream antibody drug production.

1. Monoclonal Antibody Purification Media: A Mature System of Classic Processes

Monoclonal antibody purification media is the most widely used and technically well-established category in the antibody industry and serves as the technological backbone of the entire antibody purification media field. It forms a complete process matrix centered on Protein A affinity media, supplemented by ion exchange, hydrophobic interaction, mixed-mode, and other types of media, supporting the classic three-step purification route of 'affinity capture - intermediate purification - final polishing': The first step uses Protein A affinity media to specifically bind the Fc region of IgG molecules, enriching the target antibody from the cell culture supernatant in one step, with a typical purity of over 95%; the second step uses cation exchange media to remove protein aggregates and charge variants; the third step employs flow-through anion exchange or mixed-mode media to remove trace host proteins, endotoxins, and viral impurities.

With the large-scale launch of monoclonal antibody biosimilars, the performance upgrades of monoclonal antibody purification media are increasingly focused on production efficiency and cost control: high dynamic binding capacity shortens production cycles and reduces media usage; the ability to withstand in-place cleaning with 0.5 M NaOH ensures stability and compliance across multiple batches; and excellent pressure-flow performance meets the industrial production needs of large-volume chromatography columns.。

2. Bispecific Antibody Purification Protein A Media: Affinity Adaptation for Complex Molecules

Bispecific antibodies can bind to two targets at the same time, showing unique therapeutic potential in areas like tumor immunotherapy. However, their structural diversity and heterogeneity bring challenges to the purification process—bispecific molecules easily form mispaired products, half-antibodies, and homodimers, and some bispecific structures have lower binding efficiency with traditional Protein A media. Bispecific antibody purification Protein A media is a specialized affinity medium optimized to handle these specific structures.

To address the low binding efficiency of certain bispecific structures with Protein A, bispecific antibody purification Protein A media uses targeted engineering of the Protein A ligands to improve compatibility with different bispecific formats like Knobs-into-Holes and CrossMab. At the same time, optimizing the pore size distribution and ligand density of the agarose matrix helps increase recovery of the target antibody while maintaining high binding capacity. Deep removal of bispecific by-products mainly relies on subsequent ion exchange and mixed-mode polishing steps, while the core value of bispecific antibody purification Protein A media lies in achieving efficient, high-recovery affinity capture, laying a solid foundation for the following purification stages.

Purification resin

3. Fc Fusion Protein Purification Media: Custom Solutions for Fusion Molecules

Fc fusion proteins combine the extracellular domain of functional proteins with the Fc region of IgG, offering both target specificity and a long half-life, and are widely used in areas like autoimmune diseases and ophthalmology. However, these molecules have spatial configurations significantly different from natural IgG, and the fusion region can easily create steric hindrance at Fc binding sites. Conventional affinity media often face issues such as low binding capacity and insufficient recovery. Fc fusion protein purification media are specialized media developed specifically for this niche scenario.

Fc fusion protein purification media usually use Protein A ligands with long spacer arms, which reduce the impact of steric hindrance by increasing the distance between the ligand and the matrix, improving the binding efficiency of the Fc region. Some molecules may use Protein G ligands, which have a broader IgG subclass binding range and can accommodate Fc fusion proteins that bind weakly to Protein A. However, Protein G typically requires lower elution pH, so it's important to pay attention to molecular stability and aggregation risks under acidic conditions. Considering the tendency of Fc fusion proteins to aggregate, fragment, and have strong charge heterogeneity, this type of media solution often includes selected ion exchange and hydrophobic chromatography media, forming a complete purification solution from capture to polishing that better fits the molecular characteristics of fusion proteins.

4. ADC Purification Protein A Media: Specialized Media for Conjugate Refinement

Antibody-drug conjugates (ADCs) link small molecule cytotoxins to antibodies via linkers for precise targeted killing. Their production process includes antibody preparation, conjugation reactions, and post-conjugation purification. After conjugation, the system contains free drugs, unconjugated antibodies, and ADC aggregates, placing strict demands on the selectivity and gentleness of the purification process. Protein A affinity chromatography is used in two stages in ADC production: before conjugation for capturing and purifying the naked antibody (similar to monoclonal antibody processes), and after conjugation as a recovery and crude separation step, retaining antibodies and ADCs while allowing free small molecule drugs to flow through.

ADC purification Protein A media have three core features: first, high selectivity, effectively retaining antibodies and ADCs while allowing free small molecule drugs to flow through for preliminary separation; second, mild elution conditions, with precise control of ligand affinity to reduce harsh elution pH, minimizing ADC deconjugation and aggregation risks; third, low non-specific adsorption, with hydrophilically modified matrix surfaces to reduce non-specific binding of hydrophobic linkers and small molecule drugs, lowering impurity residues. Combined with follow-up size exclusion or hydrophobic interaction chromatography, this allows production of ADCs with high purity and low free drug content.

5. AI Empowerment: MatwingsVenus™ Intelligent System Drives Media Performance Upgrades and Custom Development

MatwingsVenus™

For the selection, performance optimization, and customized development needs of four types of chromatography resins, the MatwingsVenus™ (Xiaowu™) intelligent platform uses AI-driven protein design technology at its core, providing smart support for the technical iteration and process implementation of resins for monoclonal antibody purification, bispecific antibody Protein A purification, Fc-fusion protein purification, and ADC Protein A purification. Leveraging our self-developed protein large models and closed-loop wet and dry experiments, MatwingsVenus™ (Xiaowu™) can accurately predict key functional sites affecting ligand alkali resistance, binding activity, and selectivity, upgrading the traditional trial-and-error ligand development model to a precise, targeted design approach, significantly shortening R&D cycles and reducing experimental costs.

Currently, the MatwingsVenus™ (Xiaowu™) platform has launched multiple self-developed affinity chromatography resin products covering alkali-resistant, mild-elution Protein A resins, as well as Protein L, Protein G, VHH, and other ligand series. These can be directly adapted to purification scenarios for mAbs, bispecific antibodies, Fc-fusion proteins, and ADCs. At the same time, it supports customized affinity resin development services, providing full-chain solutions from ligand design and resin preparation to process verification for special molecular structures, specific purification targets, and personalized process needs, helping pharmaceutical companies quickly establish efficient and stable proprietary purification processes.

6. Conclusion

From an industry perspective, the four types of resins correspond to different development stages and market positioning of antibody drugs: monoclonal antibody purification resins are the foundation of the industry, with the largest market size and highest technical maturity; bispecific antibody Protein A resins and ADC Protein A resins are the fastest-growing segments, with stronger technical barriers and customer loyalty; Fc-fusion protein purification resins maintain steady demand in specific therapeutic areas, with capacity and cost optimization as core development goals. As AI protein design technology continues to penetrate deeply, the performance iteration speed of domestic chromatography resins is accelerating, and platforms like MatwingsVenus™ (Xiaowu™) will further drive the intelligent upgrade of purification processes, helping China's biopharmaceutical industry achieve higher levels of independent and controllable capabilities.